Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 7/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8124240 | 0.84 | MAPT (0.66) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25247614 | 0.84 | CSNK2A1 (0.62) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL426369 | 0.84 | MAPT (0.66) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL8685929 | 0.83 | MAPT (0.69) | MEN1MAPTKMT2AALDH1A1GAA | |
| SCHEMBL7093116 | 0.82 | CSNK2A1 (0.61) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL30480033 | 0.82 | CSNK2A1 (0.61) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| Bromide SCHEMBL8360677 | 0.82 | MAPT (0.68) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8356902 | 0.82 | MAPT (0.64) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL12591893 | 0.79 | CSNK2A1 (0.57) | CSNK2A1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL22347171 | 0.79 | ALDH1A1 (0.59) | CSNK2A1MEN1MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1205472-B1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-6610857-B2 | Oxidation of 2-mercaptothiazoles with peroxidic compounds in an aqueous suspension | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-26 | — | — | US | disclosed |
| EP-1205472-A1 | Process for the preparation of dithiazolyldisulfides | BAYER AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | LANXESS DEUTSCHLAND GMBH (DE) | 2002-05-09 | — | — | US | disclosed |
| US-6248896-B1 | APPROPRIATELY SUBSTITUTED 2-MERCAPTOTHIAZOLE IS OXIDIZED WITH OXYGEN OR AN OXYGEN-CONTAINING GAS IN THE PRESENCE OF A SOLVENT AND A TERTIARY AMINE AND IRON HEMIPORPHYRAZINE. | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6124467-A | Process for the preparation of dithiazolyl disulfides | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-26 | — | — | US | disclosed |
| EP-1008591-A1 | Process for the preparation of dithiazolyldisulfides | Bayer Aktiengesellschaft (DE) | 2000-06-14 | — | — | EP | disclosed |
| US-5124450-A | Reacting solution of 2-mercaptothiazole, saturated secondary heterocyclic amine, sulfur in presence of oxygen, ammonia, copper or cerium catalyst | AKZO N.V. (NL) | 1992-06-23 | — | — | US | disclosed |
| EP-0481366-A1 | Process for the preparation of 2-Aminodithiothiazoles and 2-Aminotrithiothiazoles | Akzo Nobel N.V. (NL) | 1992-04-22 | — | — | EP | disclosed |
| US-4558135-A | AMMONIA CATALYST | AKZONA INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4307236-A | BY CATALYTIC OXIDATION OF 2-MERCAPTO THIAZOLES | AKZONA INCORPORATED (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055640-A1 | Process for the production of dithiazolyl disulfides | GPX4, PRDX3, PRDX2 | CSNK2A1 2514/4885MEN1 4693/4885MAPT 2206/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CSNK2A1 1797/4885MEN1 965/4885MAPT 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.